CFH rs4296166: Genetic Risk and Macular Degeneration
The rs4296166 single-nucleotide polymorphism is a common non-coding variant located within the complement factor H (CFH) gene region on chromosome 1. Genome-wide and candidate-gene studies have evaluated it as a genetic marker associated with susceptibility to age-related macular degeneration (AMD). While research ties this genomic locus to AMD risk, the direct causal evidence specifically isolated to rs4296166 remains limited due to extensive linkage disequilibrium across the complement gene cluster.
What each genotype means
Baseline risk profile
This genotype is considered the baseline or reference state for this variant in many studies. Research indicates that individuals with this genotype do not carry the specific allele most strongly associated with increased susceptibility to age-related macular degeneration (AMD) at this locus. Please note that AMD risk is complex and influenced by many other genetic and environmental factors.
This genotype is common, appearing in roughly 35-45% of individuals of European ancestry.
Intermediate risk profile
Carrying one copy of the T allele is associated with a statistically higher risk of developing age-related macular degeneration compared to those without it. This variant is located in a non-coding region of the CFH gene, which plays a critical role in regulating the immune system's complement pathway. You should discuss your overall eye health and any family history of vision changes with your clinician.
This heterozygous genotype is found in approximately 40-50% of individuals of European ancestry.
Increased risk profile
Individuals with this genotype carry two copies of the T allele, which has been identified in numerous studies as being associated with an increased susceptibility to age-related macular degeneration. The CFH gene is vital for controlling inflammation in the eye, and variations here may influence how that system functions over time. This association is most robust in populations of European ancestry; please consult with an eye care professional regarding routine screenings.
This homozygous genotype is present in approximately 10-15% of individuals of European ancestry.
Genetic Architecture and Genomic Location
The single-nucleotide polymorphism rs4296166 is positioned within the complement factor H (CFH) gene locus on chromosome 1q31.3. As a non-coding variant, it does not alter the primary amino acid sequence of the resulting protein. Instead, variants in this category are commonly evaluated for their potential regulatory roles, such as influencing transcript expression, splicing dynamics, or chromatin accessibility. Because the extended complement regulatory cluster contains several closely arranged genes, individual single-nucleotide polymorphisms in this region frequently reside within broad blocks of linkage disequilibrium. Consequently, non-coding markers like rs4296166 are often inherited alongside other nearby genomic variations, making it challenging to isolate their standalone functional contributions without targeted experimental fine-mapping.
Biological Function of the CFH Gene
The CFH gene encodes complement factor H, an essential circulating plasma glycoprotein that acts as a principal negative regulator of the alternative complement pathway. Part of the innate immune system, the complement cascade is responsible for neutralizing microbial pathogens, coordinating inflammatory responses, and clearing cellular debris. Complement factor H prevents hyperactivation of this defense cascade on host surfaces by accelerating the decay of alternative pathway C3 convertase enzymes and functioning as a cofactor in the enzymatic inactivation of C3b. When genetic variations perturb factor H regulation or alter local protein expression, chronic and uninhibited alternative pathway activation can occur, promoting prolonged tissue inflammation, endothelial stress, and debris accumulation in sensitive vascular beds.
Evidence Linking rs4296166 to Eye Health
Scientific literature and genome-wide association studies have repeatedly implicated the CFH genomic region in susceptibility to age-related macular degeneration (AMD), a leading cause of central visual impairment in aging populations. In association analyses, rs4296166 has exhibited statistical correlation with altered AMD risk. However, the catalog evidence strength for rs4296166 itself is rated as limited. A major confounding factor in evaluating this variant is its close linkage with other major CFH polymorphisms, such as the well-characterized Tyr402His (rs1061170) missense change and adjacent CFHR gene deletions. Researchers continue to investigate whether rs4296166 exerts an independent regulatory effect on complement expression or merely serves as a co-inherited proxy marker for neighboring pathogenic haplotypes.
Population Distribution and Ancestry Dynamics
Allele and genotype frequencies for rs4296166 display measurable variability across diverse global ancestral groups. In populations of European descent, the minor allele frequency is estimated to be approximately 35% to 45%, making both heterozygous and homozygous alternate genotypes relatively prevalent. In contrast, non-European populations, such as East Asian and African ancestry cohorts, frequently demonstrate different baseline allele distributions and distinct haplotype structures across the CFH locus. Because linkage disequilibrium patterns can diverge substantially between demographic groups, an association observed with rs4296166 in one ancestral background cannot be assumed to carry identical statistical weight or functional meaning in another.
Clinical Interpretation and Limitations
Knowledge of an individual's rs4296166 genotype is an educational insight into personal genomic variation, but it does not represent a standalone medical diagnosis. Age-related macular degeneration is a complex, multifactorial condition influenced by dozens of genetic loci alongside major non-genetic risk factors, including advanced age, cigarette smoking, and diet. Carrying risk-associated alleles at rs4296166 neither guarantees the development of macular degeneration nor eliminates risk if absent. Genetic status at this site should never be used independently to dictate clinical management, alter prescription medications, or avoid standard ophthalmic evaluations. Routine comprehensive eye exams conducted by qualified optometrists or ophthalmologists remain the established standard for assessing retinal health.
How common is this variant?
The minor allele frequency for rs4296166 is approximately 35-45% in European ancestry groups, with distinct genotype distributions observed across differing global populations.
Frequently asked questions
What is rs4296166 and what does it do?
The rs4296166 marker is a single-nucleotide polymorphism located in a non-coding region of the CFH gene. Rather than causing direct protein disruption, it serves as a genomic variant frequently evaluated for statistical associations with immune regulation and ocular traits.
Does having a risk allele at rs4296166 mean I will get macular degeneration?
No, carrying risk alleles at rs4296166 does not mean you will develop age-related macular degeneration. AMD is a multifactorial condition shaped by age, environment, smoking history, and multiple genetic loci working together.
Why is the evidence for rs4296166 considered limited?
The evidence is considered limited because rs4296166 is tightly linked to other well-established functional variants in the CFH region, such as the Y402H polymorphism. It remains unresolved whether rs4296166 drives independent biological consequences or is simply inherited alongside other causal mutations.
Should I change my eye care routine based on my rs4296166 genotype?
No, your genotype alone should not dictate medical decisions or changes to your eye care. Standard health measures, such as avoiding smoking, wearing UV-protective sunglasses, and scheduling regular dilated eye exams with an eye care professional, remain essential regardless of your genetic result.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4296166?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CFH
This regulatory variant in the CFH locus is linked to complement system dysregulation and is a recognized genetic risk factor for age-related macular degeneration.
This variant in the complement factor H gene is associated with altered regulation of the alternative complement pathway and increased susceptibility to age-related macular degeneration.
Intronic single nucleotide variant in the CFH region associated with susceptibility to age-related macular degeneration (AMD).
Common variant in the CFH locus strongly associated with risk of age-related macular degeneration (AMD).
Intronic marker in CFH forming critical susceptibility haplotypes for choroidal neovascularization and macular atrophy.
Intergenic/intronic variant within the CFH cluster contributing to phenotypic variation in retinal complement activation.